Drug Trial Radar · NCT01837745
Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
Last checked: Nov 19, 2026Latest source record: May 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
776
Actual
Start
May 13, 2013
Primary completion
Apr 1, 2022
Study completion Jan 1, 2030
Sponsor
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 23, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label randomized phase III trial, using a non-inferiority comparison design. After randomization,patients will receive either post-operative radioiodine ablation with an activity of 1.1 GBq (30 mCi) after stimulation by rhTSH, and then be followed-up (ablation group) or be followed-up (without postoperative radioiodine ablation) (follow-up group). The objective is to assess the non-inferiority of the proportion of patients without tumor-related event evaluated at three years after randomisation in the absence of radioiodine ablation (follow-up group) compared to the ablation group, in patients with low-risk differentiated thyroid cancer treated with total thyroidectomy with or without lymph node dissection (pT1am N0 or Nx, pT1b N0 or Nx)
Conditions
- Low Risk Differentiated Thyroid Cancer
Interventions
rhTSH stimulationDrug
Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
I131Drug
An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.
Follow upOther
* 10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation * 2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4) * 3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4 * 4 years (+/- 2 months) after randomization: a serum Tg/LT4 * 5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4 * 8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4 * 10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4 * 12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of patient without event at 3 years following randomizationTime frame: assessed up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institut Gustave Roussy
Villejuif, Val De Marne, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.